Cargando…
Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
The NCI Bladder Cancer Task Force convened a Clinical Trials Planning Meeting (CTPM) Workshop focused on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (NMIBC). Meeting attendees included a broad and multi-disciplinary group of clinical and research stakeholders and included leaders from...
Autores principales: | Lerner, Seth P., Bajorin, Dean F., Dinney, Colin P., Efstathiou, Jason A., Groshen, Susan, Hahn, Noah M., Hansel, Donna, Kwiatkowski, David, O’Donnell, Michael, Rosenberg, Jonathan, Svatek, Robert, Abrams, Jeffrey S., Al-Ahmadie, Hikmat, Apolo, Andrea B., Bellmunt, Joaquim, Callahan, Margaret, Cha, Eugene K., Drake, Charles, Jarow, Jonathan, Kamat, Ashish, Kim, William, Knowles, Margaret, Mann, Bhupinder, Marchionni, Luigi, McConkey, David, McShane, Lisa, Ramirez, Nilsa, Sharabi, Andrew, Sharpe, Arlene H., Solit, David, Tangen, Catherine M., Amiri, Abdul Tawab, Van Allen, Eliezer, West, Pamela J., Witjes, J. A., Quale, Diane Zipursky |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927845/ https://www.ncbi.nlm.nih.gov/pubmed/27376138 http://dx.doi.org/10.3233/BLC-160053 |
Ejemplares similares
-
“Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes
por: Pietzak, Eugene J., et al.
Publicado: (2019) -
Intrinsic subtypes and bladder cancer metastasis
por: McConkey, David J., et al.
Publicado: (2016) -
Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting
por: Cheng, Tiewei, et al.
Publicado: (2013) -
p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers
por: Choi, Woonyoung, et al.
Publicado: (2012) -
Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer
por: Kamat, Ashish M., et al.
Publicado: (2017)